3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

55.59 +0.41 ( +0.74% ) 9:52 10/18/18 Pricing delayed 20 minutes

Volume 3,233

Recent News

See All
October 11, 2018 Nevro to Report Operating Results for the Third Quarter 2018
Nevro to Host Conference Call on Monday, November 5, 2018 at 1:30 p.m. PT / 4:30 p.m. ET  Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the third quarter of 2018 after market close on Monday, November 5, 2018. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Monday, November 5, 2018. Investors interested in listening to the conference call may do so by dialing (833) 286-5807 for U.S. callers or (647) 689-4452 for international callers (Conference ID: 3989464), or logging into the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global...
September 17, 2018 Nevro Receives TGA Approval for Senza II(TM) Spinal Cord Stimulation System Delivering HF10(TM) Therapy
SUPERIOR THERAPY NOW DELIVERED IN A SMALLER AND MORE REFINED IPG REDWOOD CITY, California, Sept. 17, 2018 /PRNewswire-AsiaNet/ - Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it has received TGA approval for its next-generation Senza II(TM) Spinal Cord Stimulation (SCS) System delivering HF10(TM) therapy. The Senza II system offers the superior outcomes and clinical advantages of HF10 therapy through a smaller and more refined footprint while maintaining the performance, durability, and full-body magnetic resonance imaging (MRI) conditional labelling of the current Implantable Pulse Generator (IPG). "My colleagues and I are excited about the approval of the Senza II SCS system," said Dr. Paul Verrills, Director of Metro Pain Group in Melbourne, Australia. "The reduced size and optimized design of the Senza II IPG allow for greater patient comfort and placement...
August 30, 2018 Nevro to Present at the Morgan Stanley Global Healthcare Conference
Nevro Corp. (NASDAQ: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Nevro's management is scheduled to present on Thursday, September 13, 2018 at 3:30pm Eastern Time.  Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at: www.nevro.com. About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.